Gene expression profiling of de novo diffuse large B-cell lymphoma samples

Gene expression profiling was performed for 7 DLBCL primary clinical samples and assignment of activated B-cell-like(ABC)/germinal center B-cell-like (GCB) DLBCL classes, B-cell-associated gene signature (BAGS), and a probability of response to vincristine was performed for each sample. Diffuse large B-cell lymphoma (DLBCL) is a very heterogeneous malignant disease with diverse clinical presentation, outcome, and pathogenic mechanism. In order to better risk stratify patients there is a current need to find and validate new biomarkers of the disease. An alternatively spliced transcript of NOTCH3 missing exon 16 was identified and displayed prognostic and predictive biomarker potential. In total, 75 primary DLBCL samples were included in this study. Gene expression profiles were determined using Affymetrix GeneChip HG-U133 Plus 2.0 arrays. Gene expression of 7 samples were normalized together with expression from 68 DLBCL primary clinical samples that have been included in GSE74266 (n=47) and GSE109027 (n=21) and additional 16 other primary DLBCL samples, which has not been used further in this study.

本研究对7例弥漫大B细胞淋巴瘤（Diffuse Large B-Cell Lymphoma, DLBCL）原发性临床样本开展基因表达谱分析，并为每例样本完成活化B细胞样（activated B-cell-like, ABC）/生发中心B细胞样（germinal center B-cell-like, GCB）DLBCL亚型分型、B细胞相关基因特征（B-cell-associated gene signature, BAGS）评分，以及长春新碱应答概率预测。弥漫大B细胞淋巴瘤（DLBCL）是一种高度异质性的恶性疾病，其临床表现、预后转归及致病机制均存在显著差异。为实现更精准的患者风险分层，当前亟需发掘并验证该疾病的新型生物标志物。研究人员已鉴定出一种缺失16号外显子的NOTCH3可变剪接转录本，该转录本展现出预后及预测性生物标志物的应用潜力。本研究共计纳入75例原发性DLBCL样本，其基因表达谱通过昂飞（Affymetrix）GeneChip HG-U133 Plus 2.0芯片完成检测。本研究将7例样本的基因表达数据，与68例原发性DLBCL临床样本的表达数据进行归一化处理；该68例样本涵盖GSE74266数据集（n=47）、GSE109027数据集（n=21）中的样本，以及16例未在本研究中开展后续分析的原发性DLBCL额外样本。